

17698
022704**UTILITY PATENT APPLICATION TRANSMITTAL**

(only for new non-provisional applications under 37 CFR §1.53(b))

10/788997
USPTO
19018

Mail Stop Patent Application
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail in an envelope addressed to Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

February 27, 2004

Date of Deposit

Bonnie Stein
Signature

EL 964822454

Express Mail No.

Transmitted herewith for filing is the patent application under 37 CFR 1.53(b) of:

AVENTIS DOCKET NO.: DEAV2003/0081US NP
INVENTORS: Christian Stapper, et al.
TITLE: Cycloalkyl-Substituted Amino Acid Derivatives, Processes for Their Preparation and Their Use as Pharmaceuticals

APPLICATION ELEMENTS

- | | | |
|---|--------------|----------------------------------|
| 1. <input checked="" type="checkbox"/> *Fee Transmittal Form (e.g., PTO/SB/17)
<i>(Submit an original and a duplicate for fee processing)</i> | Total Pages | <input type="text" value="100"/> |
| 2. <input checked="" type="checkbox"/> Specification
<i>(preferred arrangement set forth below)</i>
- Descriptive title of the Invention
- Cross References to Related Applications
- Statement Regarding Fed sponsored R & D
- Reference to Microfiche Appendix
- Background of the Invention
- Brief Summary of the Invention
- Brief Description of the Drawings <i>(if filed)</i>
- Detailed Description
- Claim(s)
- Abstract of the Disclosure | Total Pages | <input type="text" value="100"/> |
| 3. <input type="checkbox"/> Drawing(s) (35 U.S.C. 113) | Total Sheets | <input type="text" value="0"/> |
| 4. Oath or Declaration | Total Pages | <input type="text" value="2"/> |
| a. <input checked="" type="checkbox"/> Newly <u>unexecuted</u> (original or copy) | | |
| b. <input type="checkbox"/> Copy from a prior application (37 CFR § 1.63(d)) | | |
| i. <input type="checkbox"/> <u>DELETION OF INVENTOR(S)</u>
Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR §§ 1.63(d)(2) and 1.33(b). | | |
| 5. Power of Attorney | Total Pages | <input type="text"/> |
| a. <input type="checkbox"/> Newly executed (original or copy) | | |
| b. <input type="checkbox"/> Copy from a prior application (37 CFR § 1.63(d)) | | |
| 6. <input type="checkbox"/> Microfiche Computer Program (<u>Appendix</u>) | | |

7. Nucleotide and/or Amino Acid Sequence Submission
(if applicable, all necessary)

 - a. Computer Readable Copy
 - b. Paper Copy (identical to computer copy)
 - c. Statement verifying identity of above copies

If a CONTINUING Application, check appropriate box, and supply the requisite information:

Continuation Divisional Continuation-in-part

of prior application no: _____, filed _____,

Examiner _____, Group/Art Unit _____.

(The cross reference has been/will be inserted here.)

 This Application claims priority from German Application No. 10308355.3 filed February 27, 2003; and
this application claims the benefit of U.S. Provisional Application No. 60/487,511 filed July 15, 2003.
(The cross reference has been/will be inserted on page one of the specification).

Incorporation By Reference (useable if filing a continuation/divisional and a copy of the declaration from the prior application is enclosed.)
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.

ACCOMPANYING APPLICATION PARTS

7. Assignment Papers (*cover sheet & document(s)*)
8. 37 CFR §3.73(b) Statement
(when there is an assignee)
9. Verified English Translation Document (*if applicable*)
10. Information Disclosure Statement (IDS)/PTO-1449 Copies of IDS Citations
11. Preliminary Amendment
12. Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)
13. *Small Entity Statement(s) Statement filed in prior application,
(PTO/SB/09-12) Status still proper and desired
14. Certified Copy of Priority Document(s) German 10308355.3
(if foreign priority is claimed)
15. Other: Application Data Sheet

CORRESPONDENCE ADDRESS

Customer Number or Bar Code Label

005487

(Insert Customer No. or Attach bar code label here)

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, New Jersey 08807-0800
Telephone (908) 231-4854
Telefax (908) 231-2626
Aventis Docket No. DEAV2003/0081US NP

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL for FY 2004

Patent fees are subject to annual revision.

 Applicant claims small entity status. See 37 CFR 1.27**TOTAL AMOUNT OF PAYMENT** (\$ 896.00)**Complete if Known**

Application Number	Not Yet Assigned
Filing Date	February 27, 2004
First Named Inventor	Christian Stapper, et al
Examiner Name	Not Yet Assigned
Group / Art Unit	Not Yet Assigned
Attorney Docket No.	DEAV2003/0081US NP

METHOD OF PAYMENT (check all that apply)

Check Credit Card Money Order Other None

 Deposit AccountDeposit Account Number **18-1982**Deposit Account Name **Aventis Pharmaceuticals Inc.**

The Commissioner is authorized to: (check all that apply)

- Charge fee(s) indicated below Credit any overpayments
 Charge any additional fee(s) during the pendency of this application
 Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account

FEES CALCULATION**1. BASIC FILING FEE**

Large Entity	Fee Code	Fee (\$)	Small Entity	Fee Code	Fee (\$)	Fee Description	Fee Paid
	1001	770	2001	375	770	Utility filing fee	
	1002	340	2002	165		Design filing fee	
	1003	530	2003	260		Plant filing fee	
	1004	770	2004	375		Reissue filing fee	
	1005	160	2005	80		Provisional filing fee	
SUBTOTAL (1)		(\$770)					

2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

		Extra Claims	Fee from below	Fee Paid
Total Claims	27	-20**= 7	x 18	= 126
Independent	1	- 3**= 0	x 88	= 0
Claims				
Multiple Dependent				


Large Entity	Fee Code	Fee (\$)	Small Entity	Fee Code	Fee (\$)	Fee Description	
	1202	18	2202	9		Claims in excess of 20	
	1201	86	2201	42		Independent claims in excess of 3	
	1203	290	2203	140		Multiple dependent claim, if not paid	
	1204	86	2204	42		**Reissue independent claims over original patent	
	1205	18	2205	9		**Reissue claims in excess of 20 and over original patent	
SUBTOTAL (2)		(\$126)					

**or number previously paid, if greater; For Reissues, see above

FEES CALCULATION (continued)**3. ADDITIONAL FEES**

Large Entity	Fee Code	Fee (\$)	Small Entity	Fee Code	Fee (\$)	Fee Description	Fee Paid
	1051	130	2051	65		Surcharge - late filing fee or oath	
	1052	50	2052	25		Surcharge - late provisional filing fee or cover sheet	
	1053	130	1053	130		Non-English Specification	
	1812	2,520	1812	2,520		For filing a request for reexamination	
	1804	920*	1804	920*		Requesting publication of SIR prior to Examiner action	
	1805	1,840*	1805	1,840*		Requesting publication of SIR after Examiner action	
	1251	110	2251	55		Extension for reply within first month	
	1252	420	2252	205		Extension for reply within second month	
	1253	950	2253	465		Extension for reply within third month	
	1254	1,480	2254	725		Extension for reply within fourth month	
	1255	2,010	2255	985		Extension for reply within fifth month	
	1401	330	2401	160		Notice of Appeal	
	1402	330	2402	160		Filing a brief in support of an appeal	
	1403	290	2403	140		Request for oral hearing	
	1451	1,510	1451	1,510		Petition to institute a public use proceeding	
	1452	110	2452	55		Petition to revive - unavoidable	
	1453	1,330	2453	650		Petition to revive - unintentional	
	1501	1,330	2501	650		Utility issue fee (or reissue)	
	1502	480	2502	235		Design issue fee	
	1503	640	2503	315		Plant issue fee	
	1460	130	1460	130		Petitions to the Commissioner	
	1807	50	1807	50		Petitions related to provisional applications	
	1806	180	1806	180		Submission of Information Disclosure Stmt	
	8021	40	8021	40		Recording each patent assignment per property (times number of properties)	
	1809	770	2809	375		Filing a submission after final rejection (37 CFR § 1.129(a))	
	1810	770	2810	375		For each additional invention to be examined (37 CFR § 1.129(b))	
	1801	770	2801	375		Request for Continued Examination (RCE)	
	1802	900	1802	900		Request for expedited examination of a design application	
Other fee (specify)							
*Reduced by Basic Filing Fee Paid		SUBTOTAL (3)		(\$)			

SUBMITTED BY**Complete (if applicable)**

Name (Print/Type)	William C. Coppola, Reg. No. 41,686	Registration No. (Attorney/Agent)	41,686	Telephone	(908) 231-4854
Signature				Date	February 27, 2004

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Alexandria, VA 22313. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Aventis Pharmaceuticals Inc. template